AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American S
Go back to AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American S| AbbVie (NYSE: ABBV) | Delayed: 233.93 -0.83 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $234.76 | 52 Week High | $68.12 | |||
| Open | $236.35 | 52 Week Low | $50.71 | |||
| Day High | $237.36 | P/E | 50.74 | |||
| Day Low | $233.55 | EPS | $4.61 | |||
| Volume | 725,388 | |||||
